343 related articles for article (PubMed ID: 18058469)
21. Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity.
Sternberg Z; Weinstock-Guttman B; Hojnacki D; Zamboni P; Zivadinov R; Chadha K; Lieberman A; Kazim L; Drake A; Rocco P; Grazioli E; Munschauer F
Mult Scler; 2008 Jul; 14(6):759-63. PubMed ID: 18505774
[TBL] [Abstract][Full Text] [Related]
22. High plasma levels of the soluble receptor for advanced glycation endproducts in patients with symptomatic carotid atherosclerosis.
Basta G; Castagnini M; Del Turco S; Epistolato MC; Righini P; Sangiorgi GM; De Caterina R; Tanganelli P
Eur J Clin Invest; 2009 Dec; 39(12):1065-72. PubMed ID: 19811526
[TBL] [Abstract][Full Text] [Related]
23. Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis.
Iłzecka J
Acta Neurol Scand; 2009 Aug; 120(2):119-22. PubMed ID: 19053950
[TBL] [Abstract][Full Text] [Related]
24. Receptor for advanced glycation end products (RAGE) polymorphisms are associated with systemic lupus erythematosus and disease severity in lupus nephritis.
Martens HA; Nienhuis HL; Gross S; van der Steege G; Brouwer E; Berden JH; de Sévaux RG; Derksen RH; Voskuyl AE; Berger SP; Navis GJ; Nolte IM; Kallenberg CG; Bijl M
Lupus; 2012 Aug; 21(9):959-68. PubMed ID: 22513366
[TBL] [Abstract][Full Text] [Related]
25. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.
Falcone C; Emanuele E; D'Angelo A; Buzzi MP; Belvito C; Cuccia M; Geroldi D
Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1032-7. PubMed ID: 15731496
[TBL] [Abstract][Full Text] [Related]
26. Plasma aminothiol compounds, but not serum tumor necrosis factor receptor II and soluble receptor for advanced glycation end products, are related to the cognitive impairment in Alzheimer's disease and mild cognitive impairment patients.
Hernanz A; De la Fuente M; Navarro M; Frank A
Neuroimmunomodulation; 2007; 14(3-4):163-7. PubMed ID: 18073509
[TBL] [Abstract][Full Text] [Related]
27. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12.
Wittkowski H; Hirono K; Ichida F; Vogl T; Ye F; Yanlin X; Saito K; Uese K; Miyawaki T; Viemann D; Roth J; Foell D
Arthritis Rheum; 2007 Dec; 56(12):4174-81. PubMed ID: 18050248
[TBL] [Abstract][Full Text] [Related]
28. Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts.
Nienhuis HL; de Leeuw K; Bijzet J; Smit A; Schalkwijk CG; Graaff R; Kallenberg CG; Bijl M
Rheumatology (Oxford); 2008 Oct; 47(10):1554-8. PubMed ID: 18701539
[TBL] [Abstract][Full Text] [Related]
29. Genetic predisposition to advanced glycation end products toxicity is related to prognosis of chronic hemodialysis patients.
Kalousová M; Jáchymová M; Germanová A; Kubena AA; Tesar V; Zima T
Kidney Blood Press Res; 2010; 33(1):30-6. PubMed ID: 20185929
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products.
Kaji Y; Usui T; Ishida S; Yamashiro K; Moore TC; Moore J; Yamamoto Y; Yamamoto H; Adamis AP
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):858-65. PubMed ID: 17251488
[TBL] [Abstract][Full Text] [Related]
31. Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients.
Chiang KH; Huang PH; Huang SS; Wu TC; Chen JW; Lin SJ
Coron Artery Dis; 2009 Jun; 20(4):267-73. PubMed ID: 19440065
[TBL] [Abstract][Full Text] [Related]
32. sRAGE is elevated in septic patients and associated with patients outcome.
Bopp C; Hofer S; Weitz J; Bierhaus A; Nawroth PP; Martin E; Büchler MW; Weigand MA
J Surg Res; 2008 Jun; 147(1):79-83. PubMed ID: 17981300
[TBL] [Abstract][Full Text] [Related]
33. V domain of RAGE interacts with AGEs on prostate carcinoma cells.
Allmen EU; Koch M; Fritz G; Legler DF
Prostate; 2008 May; 68(7):748-58. PubMed ID: 18302220
[TBL] [Abstract][Full Text] [Related]
34. The decrease of soluble RAGE levels in rheumatoid arthritis patients following hormone replacement therapy is associated with increased bone mineral density and diminished bone/cartilage turnover: a randomized controlled trial.
Pullerits R; d'Elia HF; Tarkowski A; Carlsten H
Rheumatology (Oxford); 2009 Jul; 48(7):785-90. PubMed ID: 19416946
[TBL] [Abstract][Full Text] [Related]
35. Severity of diabetic microvascular complications is associated with a low soluble RAGE level.
Grossin N; Wautier MP; Meas T; Guillausseau PJ; Massin P; Wautier JL
Diabetes Metab; 2008 Sep; 34(4 Pt 1):392-5. PubMed ID: 18701333
[TBL] [Abstract][Full Text] [Related]
36. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).
Lam JK; Wang Y; Shiu SW; Wong Y; Betteridge DJ; Tan KC
Diabet Med; 2013 Jun; 30(6):702-9. PubMed ID: 23432638
[TBL] [Abstract][Full Text] [Related]
37. The measurements of RAGE, VEGF, and AGEs in the plasma and follicular fluid of reproductive women: the influence of aging.
Fujii EY; Nakayama M
Fertil Steril; 2010 Jul; 94(2):694-700. PubMed ID: 19376511
[TBL] [Abstract][Full Text] [Related]
38. Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1.
Pullerits R; Brisslert M; Jonsson IM; Tarkowski A
Arthritis Rheum; 2006 Dec; 54(12):3898-907. PubMed ID: 17133598
[TBL] [Abstract][Full Text] [Related]
39. Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD).
Leonardis D; Basta G; Mallamaci F; Cutrupi S; Pizzini P; Tripepi R; Tripepi G; De Caterina R; Zoccali C
Nutr Metab Cardiovasc Dis; 2012 Sep; 22(9):748-55. PubMed ID: 21470837
[TBL] [Abstract][Full Text] [Related]
40. The receptor for advanced glycation endproducts and its ligands in patients with myasthenia gravis.
Moser B; Bekos C; Zimprich F; Nickl S; Klepetko W; Ankersmit J
Biochem Biophys Res Commun; 2012 Mar; 420(1):96-101. PubMed ID: 22405771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
